Skip to main content

Table 4 Clinical and laboratory characteristics in death group and survival group

From: The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014)

Clinical and laboratory parametersDeath group (n = 4)Survival group (n = 18)P
Age56.8 ± 12.558.4 ± 9.30.760
Sex  0.671
 Male (%)5 (71.4)9 (60) 
 Female (%)2 (28.6)6 (40) 
Drug duration (days)15.0 ± 6.513.7 ± 9.40.792
Drug total dose (mg)4500 ± 19443977.8 ± 2759.70.726
WBC (× 103/uL)9.0 ± 7.16.6 ± 2.70.254
CK (U/L)27,111.3 ± 29,658.819,769.7 ± 12,078.80.416
LDH (U/L)3681.5 ± 3142.22018.2 ± 710.60.042
AST (U/L)1495.8 ± 718.3967.3 ± 553.90.622
ALT (U/L)420.3 ± 263.7374.6 ± 235.10.736
Albumin (g/dL)2.8 ± 0.32.8 ± 0.70.957
BUN (mg/dL)64.7 ± 22.522.0 ± 20.10.001
Creatinine (mg/dL)4.5 ± 1.91.3 ± 1.70.003
Sodium (mmol/L)126.9 ± 3.8137.6 ± 5.20.001
Potassium (mmol/L)5.3 ± 0.94.4 ± 0.50.019
Hospital days21.8 ± 11.621.1 ± 9.60.908
Clinical signs and symptoms
 Muscle pain (%)7 (100)13 (86.7)1.000
 Muscle weakness (%)3 (42.9)6 (40.0)0.616
 Oliguria (%)4 (57.1)0 (0)0.135
 Dark urine (%)2 (28.6)1 (6.7)1.000
LC (%)4 (100)15 (83.3)1.000
Child-Pugh classification  0.312
 A (%)0 (0)3 (20.0) 
 B (%)0 (0)7 (46.7) 
 C (%)4 (100)5 (33.3) 
Severe hepatic derangement4 (100)5 (33.3)0.017
Etiology of LC  1.000
 Hepatitis B (%)3 (75)9 (60) 
 Hepatitis C (%)0 (0)2 (13.3) 
 Alcohol (%)1 (25)3 (20) 
 Cryptogenic (%)0 (0)1 (6,7) 
ARF (%)4 (100)3 (16.7)0.005
  1. WBC White Blood Cell, CK Creatine Kinase, LDH Lactate Dehydrogenase, AST Aspartate Transaminase, ALT Alaninine Transminase, BUN Blood Urea Nitrogen, DM Diabetes Mellitus, ARF Acute Renal Failure, LC Liver Cirrhosis